Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349668 | 0.86 | CCNA2 (0.62) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL6341559 | 0.86 | CCNA2 (0.62) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL29972030 | 0.82 | CCNA2 (0.58) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL15318182 | 0.80 | RAB9A (0.53) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL21687025 | 0.80 | CCNA2 (0.51) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL25143450 | 0.80 | CCNA2 (0.63) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL31665052 | 0.80 | CCNA2 (0.63) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL4420465 | 0.80 | RAB9A (0.57) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL6341557 | 0.79 | CCNA2 (0.85) | CCNA2CDK2CCNA1RAB9ANPC1 | |
| SCHEMBL19538989 | 0.79 | CCNA2 (0.55) | CCNA2CDK2CCNA1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4316492-B1 | COMBINATION OF A MULTIKINASE INHIBITOR WITH A PD-1/PD-L1 ANTIBODY AND USES THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-3447056-B1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20250082650-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-03-13 | — | — | US | disclosed |
| EP-4316492-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | Transthera Sciences (Nanjing), Inc. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| WO-2022206758-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | 药捷安康(南京)科技股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115120598-A | Combined use of multi-kinase inhibitors | 药捷安康(南京)科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210130354-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-2121619-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC Immune S.A. (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008061796-A2 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-6118008-A | FIBER-REACTIVE DYE; HAIR DYE | L'OREAL (FR) | 2000-09-12 | — | — | US | disclosed |
| EP-0900206-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997042173-A1 | NEW DIAMINO PYRAZOLS, THEIR SYNTHESIS, KERATIN FIBRE DYEING COMPOSITIONS CONTAINING THEM, KERATIN FIBRE DYEING METHODS | L'OREAL (FR) | 1997-11-13 | — | — | WO | disclosed |
| WO-1992017470-A1 | IMIDAZOLES | RHONE-POULENC RORER LIMITED (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0506437-A1 | Imidazoles | RHONE POULENC RORER LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130354-A1 | MULTI-KINASE INHIBITOR COMPOUND, AND CRYSTAL FORM AND USE THEREOF | MAP2K5, MAP3K1, MAP3K19 | CCNA2 796/4885CDK2 192/4885CCNA1 590/4885 |
| US-20250082650-A1 | COMBINED USE OF MULTIKINASE INHIBITOR | PDCD1, CD274, PDCD1LG2 | CCNA2 2685/4885CDK2 650/4885CCNA1 1160/4885 |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | MAP3K1, MAP3K5, MAP3K2 | CCNA2 538/4885CDK2 182/4885CCNA1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.